Clinical trial
A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb…
NCT00349284 · Solvay Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00349284 |
|---|---|
| Title | A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome |
| Official title | A Randomised, Double-Blind Study Comparing the Efficacy and Safety of 145 mg Fenofibrate, 10 mg Ezetimibe and Their Combination in Patients With Type IIb Dyslipidemia and Features of the Metabolic Syndrome |
| Lead sponsor | Solvay Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hyperlipidemia Combined |
| Intervention type | Drug |
| Interventions | Combination of 145 mg fenofibrate and 10 mg ezetimibe |
| Enrollment | 181 |
| Start date | Jan 1, 2005 |
| First posted | Jul 6, 2006 |
| Last update posted | Sep 3, 2007 |
| Countries | Belgium, France, Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: